Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease.
We report a case of refractory adult-onset Still's disease (AOSD) successfully controlled with anakinra, an interleukin-1 (IL-1) receptor antagonist. The patient was a 23-year-old Japanese woman with AOSD who could not be induced into remission despite of two courses of pulsed methylprednisolone followed by high-dose glucocorticoid administration in conjunction with high-dose intravenously administered gamma-globulin and methotrexate. To the best of our knowledge, this is the first case report in Japan of AOSD remission induced with anakinra.
Tamaki
Hiromichi
H
Section of Allergy and Rheumatology, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku Tokyo, 104-8560, Japan. chitama@luke.or.jp
Shimizu
Hisanori
H
Hiraoka
Eiji
E
Uechi
Eishi
E
Kishimoto
Mitsumasa
M
Yamaguchi
Kenichi
K
Okada
Masato
M
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D013256:Steroids / Q000627:therapeutic use; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy*; D017211:Treatment Failure; D055815:Young Adult
D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D013256:Steroids